

Hongyong He

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1135169/publications.pdf>

Version: 2024-02-01

40
papers

1,035
citations

516710

16
h-index

477307

29
g-index

41
all docs

41
docs citations

41
times ranked

1257
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral Foxp3+ROR γ 3+ T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1-11.	4.2	9
2	Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness. <i>Annals of Surgery</i> , 2022, 275, e163-e173.	4.2	17
3	Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients. <i>Annals of Surgery</i> , 2022, 275, e626-e635.	4.2	95
4	TIM3+ cells in gastric cancer: clinical correlates and association with immune context. <i>British Journal of Cancer</i> , 2022, 126, 100-108.	6.4	12
5	OUP accepted manuscript. <i>Gastroenterology Report</i> , 2022, 10, goab054.	1.3	2
6	Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer. , 2022, 10, e004047.		12
7	<scp>Lymphocyteâ€activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epsteinâ€Barr virusâ€positive and MLH1â€defective gastric cancer patients</scp>. <i>International Journal of Cancer</i> , 2021, 148, 759-768.	5.1	15
8	Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1915560.	4.6	17
9	Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 6439-6450.	1.5	16
10	ASO Author Reflections: Optimization of Tumor Therapy for the Specific Immune Microenvironment of Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6451-6452.	1.5	1
11	Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. <i>Nature Communications</i> , 2021, 12, 3080.	12.8	34
12	Tumor size and perineural invasion predict outcome of gastric high-grade neuroendocrine neoplasms. <i>Endocrine Connections</i> , 2021, 10, 947-954.	1.9	6
13	Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. <i>European Journal of Cancer</i> , 2021, 157, 114-123.	2.8	15
14	CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1831-1840.	4.2	32
15	Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. <i>Oncolmmunology</i> , 2021, 10, 1975386.	4.6	14
16	Tumor-infiltrating podoplanin ⁺ cells in gastric cancer: clinical outcomes and association with immune contexture. <i>Oncolmmunology</i> , 2020, 9, 1845038.	4.6	7
17	Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1590.	7.1	128
18	Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response. <i>Oncolmmunology</i> , 2020, 9, 1856468.	4.6	8

#	ARTICLE	IF	CITATIONS
19	Intratumoral CD103 ⁺ CD4 ⁺ T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients. <i>Oncolmmunology</i> , 2020, 9, 1844402.	4.6	14
20	Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1327-1336.	4.2	16
21	Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103+CD8+ T cells conferring favourable prognosis. <i>British Journal of Cancer</i> , 2020, 122, 1525-1534.	6.4	34
22	Poor clinical outcomes of intratumoral dendritic cell- α specific intercellular adhesion molecule 3 α -grabbing non-integrin α -positive macrophages associated with immune evasion in gastric cancer. <i>European Journal of Cancer</i> , 2020, 128, 27-37.	2.8	28
23	Laparoscopic versus open total gastrectomy for clinical stage I gastric cancer: Morbidity and mortality results from a prospective randomized multicenter controlled trial (CLASSO2).. <i>Journal of Clinical Oncology</i> , 2020, 38, 378-378.	1.6	1
24	Single Purse-String Suture for Reinforcement of Duodenal Stump During Laparoscopic Radical Gastrectomy for Gastric Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1020.	2.8	3
25	Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. <i>Gut</i> , 2019, 68, 1764-1773.	12.1	219
26	C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. <i>Oncolmmunology</i> , 2018, 7, e1433517.	4.6	16
27	CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 261-269.	4.2	43
28	Study on safety of laparoscopic total gastrectomy for clinical stage I gastric cancer: the protocol of the CLASSO2 α 01 multicenter randomized controlled clinical trial. <i>BMC Cancer</i> , 2018, 18, 944.	2.6	19
29	Decreased expression of granulocyte-macrophage colony-stimulating factor is associated with adverse clinical outcome in patients with gastric cancer undergoing gastrectomy. <i>Oncology Letters</i> , 2017, 14, 4701-4707.	1.8	2
30	Association of O ⁶ -Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. <i>JAMA Surgery</i> , 2017, 152, e173120.	4.3	22
31	Tumor-infiltrating β 1T cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. <i>Oncolmmunology</i> , 2017, 6, e1353858.	4.6	38
32	CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients. <i>Oncotarget</i> , 2017, 8, 20328-20339.	1.8	10
33	Alcohol consumption adjusted by aldehyde dehydrogenase 2 genotype: A potential risk factor for gastric cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, e15541-e15541.	1.6	0
34	Risk factors associated with early postoperative complications following laparoscopic total gastrectomy: Experience from the Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) group.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15544-e15544.	1.6	0
35	Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. <i>Scientific Reports</i> , 2016, 6, 38364.	3.3	4
36	Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery. <i>Tumor Biology</i> , 2016, 37, 12635-12642.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Survival benefit of greater number of lymph nodes dissection for advanced node-negative gastric cancer patients following radical gastrectomy. Japanese Journal of Clinical Oncology, 2016, 46, 63-70.	1.3	22
38	Interleukin-13 receptor $\hat{1}\pm 2$ is associated with poor prognosis in patients with gastric cancer after gastrectomy. Oncotarget, 2016, 7, 49281-49288.	1.8	20
39	Upregulated Expression of C-X-C Chemokine Receptor 4 Is an Independent Prognostic Predictor for Patients with Gastric Cancer. PLoS ONE, 2013, 8, e71864.	2.5	31
40	Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. Cancer Science, 2012, 103, 1296-1303.	3.9	38